be visible on the BioBusiness market ISSN 2300-0228

Log in | Register

Pivotal announces participation in two clinical trials with a novel investigational immunotherapy drug to treat melanoma and lung cancer
Impressions from the visit to Wageningen, the specter of famine, CRISPR Cas9 to the rescue!
Reach out to potential partners and customers in the Danish-Swedish life science cluster, Medicon Valley
Central European Healthcare Expo (20-21.05.2020 Global Expo Warsaw)
The world of healthcare ...

All articles

Filters:

Show search box

2013-11-12

Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Vintafolide - a chance for Platinum-Resistant Ovarian Cancer treatment.

Merck, one of the leaders in production of pharmaceuticals, put its new medicine under review. It is called vintafolide, MK-8109 and it is an injectable drug conjugate consisting of folate (vitamin B9) linked to alkaloid chemotherapy agent, desacetylvinblastine monohydrazine (DAVLBH). ... Read more

Tags medicine , cancer , Merck , MSD , cancer targetting

2013-11-04

Merck Serono and Selvita Announce Research Collaboration in Cancer

Merck Serono and Selvita Announce Research Collaboration in Cancer

Darmstadt, Germany, October 24, 2013 – Merck Serono, the biopharmaceutical division of Merck, and Selvita, a biotechnology company based in Poland, announced today that they have entered into a collaboration to jointly discover small molecule based drugs targeting proteins involved in cancer cell met... Read more

Tags poland , cancer , Selvita , Merck , Serono , Collaboration